

Product Data Sheet

PRAMEF17 siRNA (Human)

Source	Reactivity		Applications	
	н		RNAi	
•		expression us		
-	-		•	
	391004 (Human)			
Q5VT/	Q5VTA0 (Human)			
> 97%	> 97%			
ol Oligor	Oligonucleotide synthesis is monitored base by base through trityl analysis to ensu			rityl analysis to ensure
appro	propriate coupling efficiency. The oligo is subsequently purified by affinity-solid			
phase	e extraction. The anne	aled RNA dupl	ex is further analyzed	d by mass
spect	spectrometry to verify the exact composition of the duplex. Each lot is compared to			
the pi	revious lot by mass sp	ectrometry to	ensure maximum lot	-to-lot consistency.
We of	ffers pre-designed sets	s of 3 different	target-specific siRNA	A oligo duplexes of
huma	human PRAMEF17 gene. Each vial contains 5 nmol of lyophilized siRNA. The			
duple	duplexes can be transfected individually or pooled together to achieve knockdown			
of the	of the target gene, which is most commonly assessed by qPCR or western blot.			
			15 nmol	30 nmol
	•) - A		5 nmol x 2
				5 nmol x 2
	PRAM design Lyoph PRAM 39100 Q5VT > 97% Oligon appro phase spect the pr We of huma duple of the PRAM	SyntheticHsiRNA to inhibit PRAMEF17PRAMEF17 siRNA (Human)designed to knock down geLyophilized powderPRAMEF17PRAME family member 17391004 (Human)Q5VTA0 (Human)> 97%Oligonucleotide synthesis is appropriate coupling efficie phase extraction. The anne spectrometry to verify the e the previous lot by mass spWe offers pre-designed sets human PRAMEF17 gene. Ea duplexes can be transfected of the target gene, which isComponentPRAMEF17 siRNA (Human	Synthetic H siRNA to inhibit PRAMEF17 expression us PRAMEF17 siRNA (Human) is a target-speedesigned to knock down gene expression Lyophilized powder PRAMEF17 PRAMEF17 PRAME family member 17 391004 (Human) Q5VTA0 (Human) Q5VTA0 (Human) > 97% Oligonucleotide synthesis is monitored base appropriate coupling efficiency. The oligo phase extraction. The annealed RNA duple spectrometry to verify the exact compositient the previous lot by mass spectrometry to We offers pre-designed sets of 3 different human PRAMEF17 gene. Each vial contain duplexes can be transfected individually of the target gene, which is most common	SyntheticHRNAisiRNA to inhibit PRAMEF17 expression using RNA interference PRAMEF17 siRNA (Human) is a target-specific 19-23 nt siRNA of designed to knock down gene expression. Lyophilized powder PRAMEF17PRAMEF17amesPRAME family member 17 391004 (Human) Q5VTA0 (Human) > 97%Oligonucleotide synthesis is monitored base by base through the appropriate coupling efficiency. The oligo is subsequently puri- phase extraction. The annealed RNA duplex is further analyzed spectrometry to verify the exact composition of the duplex. Ea the previous lot by mass spectrometry to ensure maximum lot We offers pre-designed sets of 3 different target-specific siRNA human PRAMEF17 gene. Each vial contains 5 nmol of lyophilized duplexes can be transfected individually or pooled together to of the target gene, which is most commonly assessed by qPCRComponent15 nmolPRAMEF17 siRNA (Human) - A5 nmol x 1

Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC-Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb-Rabbit, S- Sheep, Z- Zebrafish

COHESION BIOSCIENCES LIMITED

WEB	ORDER	SUPPORT	CUSTOM
www.cohesionbio.com	order@cohesionbio.com	techsupport@cohesionbio.com	custom@cohesionbio.com



Product Data Sheet

PRAMEF17 siRNA (Human) - C	5 nmol x 1	5 nmol x 2
Negative Control	2.5 nmol x 1	2.5 nmol x 2
DEPC Water	1 ml x 1	

Directions for Use

We recommends transfection with 10 nM - 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For example, resuspend one tube of 5 nmol siRNA oligo in 250 μ l of DEPC water to get a final concentration of 20 μ M.

Plate	Final volume	Final concentration	siRNA (20 μM)	Lipofectamin
	of medium	of siRNA		2000
		100 nM	0.5 μl	0.25 μl
96-well	100 μl	50 nM	0.25 μl	0.25 μl
		10 nM	0.05 μl	0.25 μl
24-well 5		100 nM	2.5 μl	1 µl
	500 μl	50 nM	1.25 μl	1 µl
		10 nM	0.25 μl	1 µl
		100 nM	5 μl	2 µl
12-well 1	1 ml	50 nM	2.5 μl	2 µl
		10 nM	0.5 μl	2 µl
6-well	2 ml	100 nM	10 µl	5 µl
		50 nM	5 μΙ	5 µl
		10 nM	1 µl	5 µl

Storage/Stability

Shipped at 4 °C. Store at -20 °C for one year.

Application key: E- ELISA, WB- Western blot, IH- Immunohistochemistry, IF- Immunofluorescence, FC- Flow cytometry, IC-Immunocytochemistry, IP- Immunoprecipitation, ChIP- Chromatin Immunoprecipitation, EMSA- Electrophoretic Mobility Shift Assay, BL- Blocking, SE- Sandwich ELISA, CBE- Cell-based ELISA, RNAi- RNA interference Species reactivity key: H- Human, M- Mouse, R- Rat, B- Bovine, C- Chicken, D- Dog, G- Goat, Mk- Monkey, P- Pig, Rb-Rabbit, S- Sheep, Z- Zebrafish

COHESION BIOSCIENCES LIMITED

WEB	ORDER	SUPPORT	CUSTOM
www.cohesionbio.com	order@cohesionbio.com	techsupport@cohesionbio.com	custom@cohesionbio.com